Compare, Analyse VENUS REMEDIES with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ADCOCK INGRAM
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ADCOCK INGRAM
Jun-14
VENUS REMEDIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs126352-   
Low Rs61254-   
Sales per share (Unadj.) Rs301.8104.8-  
Earnings per share (Unadj.) Rs-24.9-26.4-  
Cash flow per share (Unadj.) Rs2.5-21.9-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.382.3-  
Shares outstanding (eoy) m12.34168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 10.7%   
Avg P/E ratio x-3.8-11.5 32.7%  
P/CF ratio (eoy) x36.7-13.9 -265.2%  
Price / Book Value ratio x0.33.7 8.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,15451,185 2.3%   
No. of employees `0000.94.3 21.5%   
Total wages/salary Rs m3933,212 12.2%   
Avg. sales/employee Rs Th4,026.14,120.8 97.7%   
Avg. wages/employee Rs Th425.0748.3 56.8%   
Avg. net profit/employee Rs Th-331.8-1,038.3 32.0%   
INCOME DATA
Net Sales Rs m3,72417,690 21.1%  
Other income Rs m23124 18.2%   
Total revenues Rs m3,74717,814 21.0%   
Gross profit Rs m395-3,066 -12.9%  
Depreciation Rs m338764 44.3%   
Interest Rs m354479 73.9%   
Profit before tax Rs m-275-4,184 6.6%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32261 12.1%   
Profit after tax Rs m-307-4,458 6.9%  
Gross profit margin %10.6-17.3 -61.2%  
Effective tax rate %-11.5-6.2 183.7%   
Net profit margin %-8.2-25.2 32.7%  
BALANCE SHEET DATA
Current assets Rs m2,63812,957 20.4%   
Current liabilities Rs m2,3057,290 31.6%   
Net working cap to sales %8.932.0 27.9%  
Current ratio x1.11.8 64.4%  
Inventory Days Days135111 122.1%  
Debtors Days Days46124 37.4%  
Net fixed assets Rs m4,8717,552 64.5%   
Share capital Rs m12382 150.2%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,61913,885 26.1%   
Long term debt Rs m1,3744,879 28.2%   
Total assets Rs m7,50926,230 28.6%  
Interest coverage x0.2-7.7 -2.9%   
Debt to equity ratio x0.40.4 108.1%  
Sales to assets ratio x0.50.7 73.5%   
Return on assets %0.6-15.2 -4.2%  
Return on equity %-8.5-32.1 26.4%  
Return on capital %1.6-19.8 -8.0%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m5141,510 34.1%  
From Investments Rs m-123-464 26.6%  
From Financial Activity Rs m-3874,428 -8.7%  
Net Cashflow Rs m45,475 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.86 Rs / ZAR

Compare VENUS REMEDIES With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: DISHMAN PHARMA  ALKEM LABORATORIES  TORRENT PHARMA  BIOCON   GLENMARK PHARMA  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living (Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Access Now: Eight Steps to Your Eight Figure Fortune
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

VENUS REMEDIES SHARE PRICE


Feb 26, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

FEATURED VIDEOS

Nifty is Weak but Smallcaps Can Outperform

Gold 65,000 and Silver 84,000 in 2022

How Long Before a Big Stock Market Crash

I Believe the Investment of the Year Will Be...

More Featured Videos

MARKET STATS